Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tg Therapeutics (TGTX) Tax Provisions (2023 - 2025)

Tg Therapeutics has reported Tax Provisions over the past 3 years, most recently at $22.0 million for Q4 2025.

  • Quarterly results put Tax Provisions at $22.0 million for Q4 2025, up 937.28% from a year ago — trailing twelve months through Dec 2025 was -$339.8 million (down 15387.18% YoY), and the annual figure for FY2025 was -$339.8 million, down 15468.11%.
  • Tax Provisions for Q4 2025 was $22.0 million at Tg Therapeutics, up from -$365.0 million in the prior quarter.
  • Over the last five years, Tax Provisions for TGTX hit a ceiling of $22.0 million in Q4 2025 and a floor of -$365.0 million in Q3 2025.
  • Median Tax Provisions over the past 3 years was $400000.0 (2024), compared with a mean of -$37.5 million.
  • Peak annual rise in Tax Provisions hit 1306.9% in 2025, while the deepest fall reached 91346.5% in 2025.
  • Tg Therapeutics' Tax Provisions stood at $390000.0 in 2023, then soared by 444.1% to $2.1 million in 2024, then skyrocketed by 937.28% to $22.0 million in 2025.
  • The last three reported values for Tax Provisions were $22.0 million (Q4 2025), -$365.0 million (Q3 2025), and $2.7 million (Q2 2025) per Business Quant data.